horizons logo
A hand is holding a torch with whipped cream on it.

Web. Program Day - 1

LEARN MORE

September 17, 2022

Web Program Day- 2

Web. Session 1

Portland Art Museum

LEARN MORE

Summary / Abstract

Web. Session 1

Web. Session - 2

W. Bryan Hubbard is the former Chairman and Executive Director of the Kentucky Opioid Abatement Advisory Commission. He is Special Counsel to the Kentucky Attorney General's Office of Medicaid Fraud and Abuse Control, serves on the Kentucky Recovery Ready Communities Council, is a member of the Kentucky Judicial Commission on Mental Health, and a member of the Kentucky Child Support Guidelines Commission. He has served as Commissioner of the Kentucky Department of Income Support where he led the Commonwealth's Social Security Disability and Child Support Enforcement programs. He also served as a commissioner for the Kentucky Mine Safety Review Board. Prior to that, he practiced worker's compensation law across Kentucky from 2001 - 2016, representing Tyson Foods, Tennessee Valley Authority, and Walmart. Bryan was raised in the coal fields of Virginia and is the proud grandson of coal miners.

Biography

W. Bryan Hubbard, JD
he/him

Appearances

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway

Name

Title

Organization

A woman in a blue jacket is smiling in a hallway
Psychedelics in America
State initiatives to support psychedelic research and access
As the profile of psychedelics continues to grow in both clinical discourse and popular culture, the quest for the underlying mechanisms of their effects has arrived as a matter of public interest.

Over the last decade, a series of findings from neuroimaging studies has yielded a variety of interpretations of the source of their therapeautic potential. These theories have often been breathlessly reported by the press and industry in service of advancing the plausibility of psychedelic medicine.

However, no consensus exists among the neuroscience community as to the origins of psychedelics effects and benefits, and neuroimaging is only one tool among many for investigating further.

In this session, we will hear from a panel of neuroscientists working towards a better understanding of underlying mechanisms about how to better consider and interpret the state of psychedelic neuroscience.

Share by: